Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wuxi Biologics (Cayman) ( (HK:2269) ) has issued an update.
Wuxi Biologics has approved the grant of 25,575,356 restricted shares at no purchase price to 1,946 grantees, including directors, an associate of a director, and employees, under its Restricted Share Award Scheme. The shares, valued at HK$33.14 each on the grant date, will vest in four equal annual tranches over four years.
The awards are positioned as discretionary bonuses recognizing past contributions and forming part of overall remuneration, without additional performance targets beyond time-based vesting. A detailed clawback mechanism allows the board to cancel unvested shares and reclaim value in cases of termination for cause or integrity-related criminal conviction, reinforcing governance while aligning employee incentives with long-term shareholder interests.
The most recent analyst rating on (HK:2269) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. is a Hong Kong-listed biologics contract development and manufacturing organization that provides end-to-end solutions for the discovery, development, and production of biologic drugs. The company serves global pharmaceutical and biotechnology clients, focusing on large-molecule therapeutics and leveraging equity-based incentives to retain and motivate talent across its operations.
Average Trading Volume: 34,811,446
Technical Sentiment Signal: Sell
Current Market Cap: HK$140.2B
Learn more about 2269 stock on TipRanks’ Stock Analysis page.
